We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Livtencity
Published
Product name
Livtencity
Active ingredient
Maribavir
Submission type
New chemical entity
Decision
Approved
Decision date
Registration date
What this medicine was approved for
Livtencity (maribavir) was approved for the following therapeutic use:
Treatment of adults with post-transplant cytomegalovirus (CMV) infection and disease resistant, refractory or intolerant to one or more prior therapies (see 4.3 Contraindications and, 4.4 Special warnings and precautions for use).
How this medicine works
The antiviral activity of maribavir is mediated by competitive inhibition of the protein kinase activity of HCMV [human cytomegalovirus] enzyme UL97, which results in inhibition of the phosphorylation of proteins; an effect achieved at low concentrations of maribavir.
Why the TGA approved or did not approve this medicine
The decision was based on quality (chemistry and manufacturing), nonclinical (pharmacology and toxicology), clinical (pharmacology, safety and efficacy) and risk management plan information submitted by the sponsor. The benefit-risk profile of Livtencity was considered favourable for the therapeutic use approved.